Retatrutide and Caffeine: Interaction Evidence Record
At a glance
- Review question / Is there FDA-reviewed or study-specific interaction evidence for retatrutide and Caffeine?
- Best evidence / a named pharmacokinetic registry record
- Evidence snapshot / 2026-08-09
- Commercial status / no FDA-approved product or ordinary retail supply
- HealthRX.com role / independent educational review; no retatrutide product or treatment offer
Direct answer
The answer is limited. Caffeine is a dietary supplement or nutrition product. A completed phase 1 registry record specifically measured pharmacokinetic endpoints relevant to this question. That narrow experiment does not create an FDA-reviewed interaction table, an overall safety conclusion, or public-use instructions.
The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.
Evidence map for Caffeine interaction evidence
| Primary source | What the record documents | What the record cannot establish alone |
|---|---|---|
| ClinicalTrials.gov pharmacokinetic record NCT05445232 | A completed phase 1 record that measured pharmacokinetic endpoints for midazolam, warfarin, and caffeine in a defined research setting. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| Rosenstock et al., phase 2 type 2 diabetes trial report | Reports a randomized phase 2 study in 281 adults and describes glycemic, body-weight, and adverse-event endpoints. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| Jastreboff et al., phase 2 obesity trial report | Reports a randomized 48-week study in 338 adults and identifies the protocol-defined endpoints and adverse-event collection methods. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
| FDA status statement for unapproved GLP-1 drugs | Documents that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. | Does not by itself establish an approved use, public-use instruction, or conclusion beyond the source's design. |
How HealthRX.com evaluated this question
Interaction evidence has levels. A named pharmacokinetic study can measure exposure under controlled conditions; a clinical outcomes study can examine events in a defined population; an FDA label can synthesize reviewed evidence into instructions. Background use, anecdotes, and mechanism-based reasoning sit below those sources and should not be presented as settled guidance.
For this page, HealthRX.com asked: (1) Is caffeine interaction evidence named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.
Evidence checks specific to this record
Protocol provenance
Verify that the question is present in the dated protocol or analysis plan rather than introduced only after results were known. For caffeine interaction evidence, note whether the item is a primary endpoint, secondary endpoint, exploratory analysis, eligibility factor, or incidental mention. Those roles carry different evidentiary weight.
Endpoint definition
Use the protocol's exact definition, unit, assessment method, and analysis time. Similar-sounding endpoints can measure different constructs. For caffeine interaction evidence, a change in wording, threshold, or time point may materially change the research question.
Regulatory checkpoint
Search for a controlling FDA action after reviewing trials and publications. For caffeine interaction evidence, a study completion date, peer-reviewed paper, company announcement, or expanded-access entry does not replace an approval letter and approved prescribing information.
Registry-to-publication match
Match the publication to its registry identifier, enrolled population, protocol version, and prespecified outcomes. If caffeine interaction evidence appears in a paper but not in the registered plan, readers should determine whether it was added, redefined, or reported as an exploratory analysis.
Sponsor and author roles
Identify the sponsor, funding, author affiliations, data access, and stated conflicts. These facts do not invalidate a study, but they help readers evaluate independent replication, analytic transparency, and how confidently caffeine interaction evidence can be generalized.
What remains unresolved
Retatrutide has no FDA-approved prescribing information or FDA-reviewed interaction table. Mechanism-based guesses, class analogies, anecdotes, and use of Caffeine as background therapy cannot establish whether concurrent use is safe, unsafe, beneficial, or appropriate.
The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.
What evidence could change the answer
The strongest future evidence would be a registered study naming Caffeine, prespecifying pharmacokinetic or clinical endpoints, documenting exposure and timing, and publishing complete results.
Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.
Current federal and commercial status
Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX.com does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX.com offers the investigational substance.
Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.
Source selection and review method
HealthRX.com reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov pharmacokinetic record NCT05445232; Rosenstock et al., phase 2 type 2 diabetes trial report; Jastreboff et al., phase 2 obesity trial report; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.
Frequently asked questions
Is there an FDA-reviewed interaction table for Caffeine?
No. Retatrutide has no FDA-approved prescribing information and therefore no FDA-reviewed public interaction table.
Does no dedicated study mean there is no interaction?
No. Absence of a named study is an evidence gap, not proof that concurrent use is compatible or incompatible.
What source would answer the question best?
A registered study that names the substance, prespecifies pharmacokinetic or clinical endpoints, and publishes complete results would be more informative. FDA-reviewed labeling would be needed for public-use instructions.
References
- ClinicalTrials.gov. Retatrutide pharmacokinetic interaction-study record. 2026. https://clinicaltrials.gov/study/NCT05445232
- Rosenstock J, Frias J, Jastreboff AM, et al. Phase 2 retatrutide type 2 diabetes trial report. The Lancet. 2023. https://pubmed.ncbi.nlm.nih.gov/37385280/
- Jastreboff AM, Kaplan LM, Frias JP, et al. Phase 2 retatrutide obesity trial report. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
- U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7